| Literature DB >> 30971730 |
Suhita Gayen Nee' Betal1, Swati Murthy1, Michael Favara1, Gina Fong1, Joanna S Y Chan2, Sankar Addya3, Thomas H Shaffer1, Jay Greenspan1, Vineet Bhandari4, Irfan Rahman5, Zubair H Aghai6.
Abstract
Histological chorioamnionitis (HCA) is an infection of fetal membranes and complicates 5.2% to 28.5% of all live births. HCA is associated with increased mortality and morbidity in both premature and term neonates. Exposure to HCA may have long-term consequences, including an increased risk for allergic disorders and asthma later in childhood, the mechanism(s) of which are still not yet well understood. The objective of this study was to determine the mRNA transcriptome of cord blood mononuclear leukocytes from term neonates to identify key genes and pathways involved in HCA. We found 366 differentially expressed probe IDs with exposure to HCA (198 upregulated, 168 downregulated). These transcriptomes included novel genes and pathways associated with exposure to HCA. The differential gene expression included key genes regulating inflammatory, immune, respiratory and neurological pathways, which may contribute to disorders in those pathways in neonates exposed to HCA. Our data may lead to understanding of the role of key genes and pathways identified on the long-term sequelae related to exposure to HCA, as well as to identifying potential markers and therapies to prevent HCA-associated complications.Entities:
Mesh:
Year: 2019 PMID: 30971730 PMCID: PMC6458165 DOI: 10.1038/s41598-019-42205-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Top 10 differentially up- or down-regulated genes after exposure to HCA.
| ProbeID | Gene Symbol | HCA Group Average Expression | Control Group Average Expression | Fold Change | Up/Down | P-value |
|---|---|---|---|---|---|---|
| TC17001604.hg.1 |
| 1389.16 | 344.89 |
|
| 0.0245 |
| TC04002938.hg.1 |
| 364.56 | 136.24 |
| 0.012 | |
| TC07000288.hg.1 |
| 1652 | 643.59 |
| 0.0117 | |
| TC03000255.hg.1 |
| 765.36 | 304.44 |
| 0.0417 | |
| TC04001682.hg.1 |
| 643.59 | 256 |
| 0.0167 | |
| TC17000604.hg.1 |
| 13216.02 | 5556.65 |
| 0.0312 | |
| TC07001299.hg.1 |
| 140.07 | 60.13 |
| 0.0002 | |
| TC07001300.hg.1 |
| 179.77 | 79.89 |
| 4.50xE-05 | |
| TC04002939.hg.1 |
| 240.52 | 112.99 |
| 0.0173 | |
| TC17001603.hg.1 |
| 20594.91 | 9946.68 |
| 0.0478 | |
| TC01003638.hg.1 |
| 252.48 | 9089.59 |
|
| 0.0205 |
| TC04002953.hg.1 |
| 313 | 1884.54 |
| 0.001 | |
| TC01001749.hg.1 |
| 2352.53 | 13034.07 |
| 0.008 | |
| TC05001854.hg.1 |
| 385.34 | 2005.85 |
| 0.0022 | |
| TC19001593.hg.1 |
| 1448.15 | 7082.29 |
| 0.0138 | |
| TC21001069.hg.1 |
| 3956.48 | 17438.64 |
| 0.0257 | |
| TC12001216.hg.1 |
| 178.53 | 765.36 |
| 0.0365 | |
| TC03000276.hg.1 |
| 657.11 | 2683.69 |
| 0.0011 | |
| TC09000508.hg.1 |
| 143.01 | 580.04 |
| 0.0128 | |
| TC03001357.hg.1 |
| 2683.69 | 9345.14 |
| 0.0208 |
Differential expression of genes related to immune response after exposure to HCA.
| Gene Symbol | Up/Down | Fold Change | P-value | HCA Group Average Expression | Control Group Average Expression |
|---|---|---|---|---|---|
|
|
|
| 0.0417 | 765.36 | 304.44 |
|
|
| 0.0002 | 140.07 | 60.13 | |
|
|
| 0.0118 | 52498.92 | 23010.42 | |
|
|
| 0.000045 | 179.77 | 79.89 | |
|
|
| 0.0433 | 1458.23 | 809.00 | |
|
|
| 0.0233 | 1734.13 | 1002.93 | |
|
|
| 0.0201 | 33.36 | 20.68 | |
|
|
| 0.0086 | 4482.23 | 2778.33 | |
|
|
| 0.0294 | 153.28 | 96.34 | |
|
|
| 0.0121 | 2646.74 | 1698.45 | |
|
|
| 0.0275 | 694.58 | 448.82 | |
|
|
| 0.0155 | 989.12 | 648.07 | |
|
|
|
| 0.0205 | 252.48 | 9089.59 |
|
|
| 0.001 | 313.00 | 1884.54 | |
|
|
| 0.0022 | 385.34 | 2005.85 | |
|
|
| 0.0138 | 1448.15 | 7082.29 | |
|
|
| 0.0011 | 657.11 | 2683.69 | |
|
|
| 0.0128 | 143.01 | 580.04 | |
|
|
| 0.0208 | 2683.69 | 9345.14 | |
|
|
| 0.0262 | 1192.69 | 3304.00 | |
|
|
| 0.0023 | 2256.70 | 5330.30 | |
|
|
| 0.0125 | 280.14 | 652.58 | |
|
|
| 0.042 | 680.29 | 1573.76 | |
|
|
| 0.0404 | 112.21 | 229.13 | |
|
|
| 0.0059 | 116.16 | 235.57 | |
|
|
| 0.0083 | 47.18 | 91.14 | |
|
|
| 0.0308 | 288.01 | 512.00 | |
|
|
| 0.0422 | 256.00 | 451.94 | |
|
|
| 0.048 | 164.28 | 284.05 | |
|
|
| 0.0351 | 413.00 | 657.11 |
Up-regulated genes after exposure to HCA and their functions.
| Gene Symbol | Gene name | Function |
|---|---|---|
|
| C-C Motif Chemokine Receptor 2, Receptor for monocyte chemoattractant protein-1 | Role in asthma, inflammation |
|
| GTPase, Immunity-Associated Protein family member 4 | T- and B-cell development and survival, T-cell apoptosis |
|
| Killer Cell Lectin-Like Receptor Subfamily C, Member 3 | Natural Killer receptor gene, role in cell proliferation |
|
| T Cell Receptor Gamma Variable 3 | Peptide antigen binding, immune response |
|
| Histamine Receptor H2 | Histamine receptor gene, role in hypersensitiviy |
|
| Cholinergic Receptor Nicotinic Alpha 7 Subunit | Alter airway morphometry and lung function |
|
| GTPase, Immune-Associated Nucleotide-Binding Protein 7 | Regulators of lymphocyte survival and homeostasis (Schwefel D 2013) |
|
| Rhotekin 2 | Role in apoptosis |
|
| Cluster of differentiation 99, Single-chain type-1 glycoprotein | Role in cell adhesion, migration, death, differentiation and diapedesis, and it influences processes associated with inflammation, immune responses (pasello M 2018) |
|
| Vanin 2 | Hematopoietic cell trafficking, Role in oxidative-stress |
|
| Phosphatase And Tensin Homolog | Role in asthma, hyper-reactivity |
Down-regulated genes after exposure to HCA and their functions.
| Gene symbol | Gene name | Function |
|---|---|---|
|
| Prostaglandin-Endoperoxide Synthase 2 | Role in asthma and lung inflammation, hyperoxia induced lung injury |
|
| G0/G1 Switch 2 | Regulation of lipid metabolism |
|
| Amphiregulin, Colorectum Cell-Derived Growth Factor | Role in asthma, airway modelling, BPD |
|
| Heparin-Binding Epidermal Growth Factor | Role in asthma, airway modelling |
|
| Plasminogen Activator, Urokinase Receptor | Role in asthma, COPD |
|
| Cathelicidin Antimicrobial Peptide | Role in asthma, lung infection |
|
| Nuclear Receptor Subfamily 4 Group A Member 3 | Regulates neutrolphils number and survival, Treg cell development through activation of Foxp3 |
|
| Lactotransferrin | Role in asthma, BPA VAP |
|
| Fc Fragment Of Immunoglobulin Alpha Receptor | SNP associated with allergic asthma (Jasek M 2004) |
|
| Nuclear Factor, Interleukin 3 Regulated | Critical regulator for IgE production and airway hyper-responsiveness. |
|
| Phosphodiesterase 4B | Role in asthma, inhibitors use as treatment |
|
| Adhesion G Protein-Coupled Receptor E3 | Modulator of immune cell funtion |
|
| C-X-C Motif Chemokine Ligand 1 | Role in BPD, lung alveolization |
|
| T Cell-Interacting, Activating Receptor On Myeloid Cells 1 | Upregulated by LPS, recruitment to site of inflammation |
|
| Snail Family Transcriptional Repressor 1 | Β-catenin target gene, lung fibrosis |
|
| Zinc Finger Protein 331 | Pathogenesis of asthma |
|
| Zinc Finger CCCH-Type Containing 12A | Regulates the development and function of IL-5-producing TH2 cells through the Notch/Gata3 pathway |
|
| Interleukin 1 Receptor Associated Kinase 2 | IRAK2 Attenuate the Proinflammatory Effects of IL-33 in Asthma-like Mouse Models. |
Functions modified with exposure to HCA.
| Modified Functions | Number of Genes Involved | Range of p-value for genes involved |
|---|---|---|
| Cellular Movement | 46 | 1.26E-13-1.52E-03 |
| Immune Cell Trafficking | 38 | 1.26E-13-1.03E-03 |
| Inflammatory Disease | 46 | 7.43E-13-1.25E-03 |
| Cell Death and Survival | 60 | 1.5E-12-1.46E-03 |
| Immunological Disease | 47 | 2.74E-12-1.25E-03 |
| Connective Tissue Disorders | 38 | 3.3E-12-1.47E-03 |
| Inflammatory Response | 55 | 3.55E-11-1.38E-03 |
| Neurological Disease | 32 | 1.29E-10-1.38E-03 |
| Cell-To-Cell Signaling and Interaction | 40 | 3.45E-10-1.51E-03 |
| Hematological System Development and Function | 44 | 3.45E-10-1.51E-03 |
| Cellular Growth and Proliferation | 49 | 2.3E-07-1.46E-03 |
| Hematopoiesis | 27 | 4.16E-07-9.74E-04 |
| Lymphoid Tissue Structure and Development | 33 | 4.16E-07-9.74E-04 |
| Cellular Function and Maintenance | 42 | 4.95E-07-1.52E-03 |
| Humoral Immune Response | 15 | 5.54E-07-1.4E-03 |
| Infectious Diseases | 28 | 6.5E-07-1.39E-03 |
| Respiratory Disease | 19 | 6.5E-07-1.23E-03 |
| Cell Cycle | 26 | 6.84E-07-1.49E-03 |
| Gene Expression | 37 | 6.84E-07-1.5E-03 |
| Free Radical Scavenging | 14 | 7.69E-06-9.02E-06 |
| Cell-mediated Immune Response | 15 | 2.3E-05-5.63E-04 |
| DNA Replication, Recombination, and Repair | 11 | 1.06E-04-4.46E-04 |
| Antimicrobial Response | 9 | 2.39E-04-2.39E-04 |
| Nervous System Development and Function | 15 | 3.11E-04-1.19E-03 |
| Post-Translational Modification | 14 | 3.43E-04-3.43E-04 |
| Hypersensitivity Response | 5 | 3.8E-04-3.8E-04 |
| Hematological Disease | 39 | 4.13E-04-1.09E-03 |
| Cellular Assembly and Organization | 6 | 8.04E-04-8.04E-04 |
| Psychological Disorders | 3 | 9.59E-04-9.59E-04 |
| Respiratory System Development and Function | 2 | 9.59E-04-9.59E-04 |
| Developmental Disorder | 12 | 1.24E-03-1.24E-03 |
| Behavior | 17 | 1.47E-03-1.47E-03 |
Canonical pathways in ingenuity pathway analysis associated with differentially expressed genes between control and HCA groups.
| Ingenuity Canonical Pathways | −log10(p-value) | Molecules involved in pathways |
|---|---|---|
| Protein Kinase A Signaling | 4.46 | PTEN,PTGS2,PTPRE,DUSP6,MYH10, NFKBIE,PDE4B,ADD2,DUSP2,NFKBID |
| PI3K/AKT Signaling | 3.32 | PTEN,PTGS2,CDKN1A,NFKBIE,NFKBID |
| IL-17A Signaling in Airway Cells | 3.12 | PTEN,CXCL1,NFKBIE,NFKBID |
| MIF-mediated Glucocorticoid Regulation | 3.09 | PTGS2,NFKBIE,NFKBID |
| MIF Regulation of Innate Immunity | 2.83 | PTGS2,NFKBIE,NFKBID |
| iCOS-iCOSL Signaling in T Helper Cells | 2.46 | PTEN,HLA-DQB1,NFKBIE,NFKBID |
| TNFR2 Signaling | 2 | NFKBIE,NFKBID |
| IL-17 Signaling | 1.99 | PTGS2,CXCL1,TIMP1 |
| 4-1BB Signaling in T Lymphocytes | 1.91 | NFKBIE,NFKBID |
| IL-1 Signaling | 1.9 | NFKBIE,IRAK2,NFKBID |
| PPAR Signaling | 1.9 | PTGS2,NFKBIE,NFKBID |
| IL-17A Signaling in Fibroblasts | 1.84 | NFKBIE,NFKBID |
| B Cell Activating Factor Signaling | 1.71 | NFKBIE,NFKBID |
| IL-8 Signaling | 1.7 | HBEGF,PTGS2,CXCL1,IRAK2 |
| p53 Signaling | 1.68 | PTEN,CDKN1A,TNFRSF10B |
| PI3K Signaling in B Lymphocytes | 1.54 | PTEN,NFKBIE,NFKBID |
| Glucocorticoid Receptor Signaling | 1.49 | CCNH,PTGS2,CDKN1A,NFKBIE,NFKBID |
| IL-10 Signaling | 1.29 | NFKBIE,NFKBID |
| T Helper Cell Differentiation | 1.29 | HLA-DQB1,IL23R |
Figure 1Ingenuity pathway analysis networks related to immune modulation and inflammatory response are presented in this figure (A–D). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) software (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) by loading 366 probe sets that were differentially expressed with HCA[19].
Figure 2Ingenuity pathway analysis networks related to neurological disease are presented in this figure (A,B). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) software (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) by loading 366 probe sets that were differentially expressed with HCA[19].
Figure 3Box plot for real-time PCR data on selected genes in the two groups (Control and HCA) are presented in this figure.
Validation of microarray data with real-time PCR.
| Gene Symbol | Microarray | Real-Time PCR | ||
|---|---|---|---|---|
| Fold Change | p-value | Fold Change | p-value | |
| GOS2 | −3.18 | 0.011 | −6.42 | 0.015 |
| AREG | −2.54 | 0.006 | −4.78 | 0.007 |
| HBEGF | −2.15 | 0.008 | −3.53 | 0.005 |
| CAMP | −1.83 | 0.005 | −2.93 | 0.023 |
| LTF | −1.73 | 0.044 | −2.56 | 0.042 |
| VNN2 | 1.56 | 0.021 | 1.55 | 0.028 |
| TRGV3 | 1.78 | 9.18E-04 | 3.67 | 0.240* |